S-Arrestin Peptides for Uveitis Autoimmunity Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uveitis, a form of eye inflammation, are limited, and there is a need for alternative therapeutic options that can effectively prevent or suppress the autoimmune response associated with this condition.
Innovation Solution
The development of specific peptides derived from S-Arrestin (S-Ag) that can bind to MHC molecules without antigen processing, potentially inducing tolerance and reducing the immune response, thereby treating or preventing uveitis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (glucocorticoid steroids and immunosuppressive agents) are used for uveitis, then inflammation is suppressed, but side effects and limitations of current therapies occur
Solution Approach 1:
The invention segments the S-Ag antigen into specific peptide fragments (e.g., SEQ ID NOs: 1-9) that can be administered separately. These segmented peptides induce tolerance to specific epitopes involved in the autoimmune response, providing targeted therapy with potentially fewer side effects compared to broad immunosuppression
Solution Approach 2:
The patent uses peptide intermediaries derived from S-Ag that act as mediators to induce peripheral tolerance. These peptides serve as intermediaries between the immune system and the self-antigen, redirecting the immune response away from pathogenicity toward tolerance, thereby treating uveitis without the harsh side effects of conventional immunosuppressants
2Reliability
If antigen-specific tolerance is induced using peptide fragments, then T cell production is suppressed, but the complexity of identifying effective peptides increases
Solution Approach 1:
The invention performs preliminary identification and characterization of immunodominant peptide epitopes from S-Ag before clinical application. By pre-screening and selecting peptides that are most likely to induce tolerance (based on immunogenicity and MHC binding predictions), the complexity of the treatment selection process is reduced while maintaining high efficacy
Solution Approach 2:
The patent systematically varies peptide parameters (amino acid sequence, length, MHC binding affinity) to identify optimal tolerogenic peptides. By changing these parameters and testing their ability to induce tolerance, the invention transforms a complex biological problem into a systematic parameter optimization process
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
The present invention relates to a composition which comprises peptides derived from S- Arrestin (retinal arrestin, S-antigen, S-Ag). The composition or peptides may be useful in the prevention and/or suppression of S-Ag autoimmunity, which is useful in the treatment and/or prevention of uveitis.